Merck Report Result of Keytruda (pembrolizumab) + Lenvima (lenvatinib) as 1L Treatment for Advanced Renal Cell Carcinoma

 Merck Report Result of Keytruda (pembrolizumab) + Lenvima (lenvatinib) as 1L Treatment for Advanced Renal Cell Carcinoma

Merck Report Result of Keytruda (pembrolizumab) + Lenvima (lenvatinib) as 1L Treatment for Advanced Renal Cell Carcinoma

Shots:

  • The P-III CLEAR study involves assessing of Lenvima (20 mg/day) + Keytruda (200 mg, IV, q3w) or in combination with everolimus (5mg, qd) vs sunitinib (50 mg, q4w) in 1,069 patients for the 1L treatment with advanced RCC
  • The trial met its 1EPs with Keytruda + Lenvima shows 61% reduction in the risk of disease progression or death, mPFS (2yrs. vs 9 mos.) 2 EPs shows 34% reduced the risk of death, ORR (71.0% vs 36.1%); CR (16.1 vs 4.2%); PR( 54.9% vs 31.9%); mDoR(25.8 vs 14.6mos)
  • Lenvima + everolimus shows 35% reduction in the risk of disease progression or death; mPFS (14.7 vs 9.2mos); CR (9.8% vs 4.2%); PR (43.7% vs 36.1%); mDOR (16.6 vs 14.6 mos.)@median follow-up 27 mos.

Click here ­to­ read full press release/ article | Ref: Merck | Image: The New York Times

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post